Browsing by Author "Güler, S"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    A Study on Developing a Communicative Rational Action Scale
    Çamli, AY; Virlanuta, FO; Palamutçuoglu, BT; Barbuta-Misu, N; Güler, S; Züngün, D
    The aim of this study is to develop a Communicative Rational Action Scale and analyze its validity and reliability. The scale has been prepared for all administrators and especially for firm administrators based on Max Weber's rationalizing theory and Jurgen Habermas' communicative action theory. The scale reveals to what extent administrators' behaviors are communicatively rational while deciding or acting. In total, 282 participants joined this study. The sample group consisted of senior administrators of 87 firms acting in Turkey's different Organized Industrial Zones or Free Zones. Data were analyzed by the SPSS 21 and AMOS 22 programs. Exploratory factor analysis and confirmatory factor analysis were applied to the obtained data. In order to test item discrimination, total item correlations were calculated and items under the value of 0.40 were removed from the scale. Exploratory factor analysis revealed 21 articles and five factors. The correlation coefficient of the 21-article scale with a similar scale is 0.979 (p < 0.001). The Cronbach's alpha value is 0.945 and the test-retest correlation parameter is r = 0.793 (p < 0.001). In conclusion, it was determined by confirmatory factor analysis that the Communicative Rational Action Scale has a good cohesion criterion, and it is a valid and reliable assessment instrument.
  • No Thumbnail Available
    Item
    Autoimmune thyroiditis detected during allergen-specific immunotherapy: a case report
    Türkeli, A; Yilmaz, O; Güler, S; Yüksel, H
    Allergen-specific immunotherapy (SIT) is a treatment modality that has been shown to be effective in the treatment of asthma, allergic rhinitis or anaphylaxis due to pollen, mite or venom hypersensitivity. Clinical and immunologic advantages of a successful immunotherapy continue for years after the treatment is finished. Local and systemic side effects have been reported to be associated with SIT, but long-term side effects have not yet been clarified. The term autoimmune thyroiditis includes many different diseases. Impairment of cellular immunity due to genetic defect of suppressor T-cells lies beneath Hashimoto thyroiditis. A 14-year-old girl diagnosed with asthma who developed findings of autoimmune thyroiditis and goiter four months after SIT with grass pollen antigens is presented to emphasize the possibility of autoimmune disease development during the course of SIT and
  • No Thumbnail Available
    Item
    Bronchiolitis in childhood: Updates on etiopathogenesis and immunologic lung injury
    Yüksel, H; Türkeli, A; Yilmaz, Ö; Güler, S
    Acute bronchiolitis is a disease characterized with bronchiolar inflammation due to viral infections in children younger than two years that is associated with wheezing, cough, tachypnea, retractions and prolonged expiration. Many pathogens, among which respiratory syncytial virus is the most common, play role in the etiology. Cellular damage due to viral pathogens and anatomic and immunological factors of the host play a role in the development of lower respiratory tract infections only in some children exposed to respiratory syncytial virus and other viruses. Viral infections in children may change Th1/Th2 immune response pattern. Severity of disease changes with the degree of inflammation due to the immune response. Moreover, an increase in disease severity may be observed due to the activation of the non-adrenergic non-cholinergic neurogenic system. Severe RSV infections may develop in children with genetic predisposition. We explained the role of environmental factors, genetic and structural susceptibility of the host, and contribution of immunologic response in this susceptibility, in addition to the role of responsible infectious agents, in the development and severe progression of bronchiolitis (Turk Arch Ped 2010; 45: 75-81)
  • No Thumbnail Available
    Item
    Characterization and immobilization of Trametes versicolor laccase on magnetic chitosan-clay composite beads for phenol removal
    Aydemir, T; Güler, S
    Laccase from Trametes versicolor was immobilized on magnetic chitosan-clay composite beads by glutaraldehyde crosslinking. The physical, chemical, and biochemical properties of the immobilized laccase and its application in phenol removal were comprehensively investigated. The structure and morphology of the composite beads were characterized by SEM, TGA, and FTIR analyses. The immobilized laccase showed better storage stability and higher tolerance to the changes in pH and temperature compared with free laccase. Moreover, the immobilized laccase retained more than 75% of its original activity after 10 cycles. The efficiency of phenol removal by immobilized laccase was about 80% under the optimum conditions after 4 h.
  • No Thumbnail Available
    Item
    Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study
    Çetinarslan, B; Çetinkalp, S; Kaya, A; Ersoy, C; Kebapçi, N; Çömlekçi, A; Tütüncü, NB; Deyneli, O; Oguz, A; Ilkova, H; Yilmaz, T; Hekimsoy, Z; Ünübol, M; Balci, MK; Atmaca, A; Dagdelen, S; Yetkin, I; Güler, S; Ötünç, G; Özhan, L
    Objective: The aim of the study was to evaluate the effectiveness and safety of insulin glargine 300 U/ mL (Gla-300) in insulin-naive patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drug (OADs) treatment in Turkey. Methods: One hundred eight patients from 20 centers enrolled in the study. Starting from baseline, Gla-300 was self-administered subcutaneously and once daily in the evening. The primary outcome was the mean change in glycated hemoglobin A1c (HbA1c) from baseline to week 24. Results: The mean (+/- SD) Hb1Ac level of 9.4% (+/- 0.8) at baseline decreased to 7.5% (+/- 0.9) at week 12 (P < .1) and to 7.3% (+/- 0.9) at week 24 (P < .1). Although none of the patients were within the target Hb1Ac level of <= 7% at baseline, the percentage of patients who achieved the target Hb1Ac level was 30.4% at week 12 and increased to 42.9% at week 24. Gla-300 treatment achieved the Hb1Ac target in 21 (19.4%) patients without experiencing a hypoglycemic event and in 27 (25.0%) patients who experienced at least one hypoglycemic event. For each self-monitoring blood glucose time point, significant improvements were observed as compared to baseline (P < .001). Statistically significant improvement (P < .001) was seen in the treatment satisfaction questionnaire - status version scores between baseline and week 24. Conclusion: This study indicated that Gla-300 is effective to provide a successful glycemic control with low risk of hypoglycemia added to OADs in insulin-naive patients with T2DM, and it has the potential to improve the quality of life of patients.